With a com­pet­i­tive Bill Si­bold tak­ing the helm at Sanofi Gen­zyme, long­time ex­ec David Meek­er makes an ex­it

When Sanofi stepped in close to six years ago and bought out Gen­zyme for $20 bil­lion, the phar­ma gi­ant pro­mot­ed David Meek­er to take the helm of the cru­cial op­er­a­tion in Boston. To­day, Meek­er says he’s leav­ing af­ter 23 years at the com­pa­ny, and he’ll be re­placed by the MS fran­chise chief Bill Si­bold.

It was Meek­er and Si­bold who man­aged the suc­cess­ful roll­out of Auba­gio and Lem­tra­da — which had to bat­tle back from a crush­ing CRL. The two MS drugs that now make up a sig­nif­i­cant part of Sanofi’s over­all rev­enue. And it’s Si­bold who was in charge of prepar­ing the launch of the new­ly ap­proved eczema drug Dupix­ent (dupilum­ab) — tapped as a like­ly megablock­buster — as well as sar­ilum­ab, which was de­layed at the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER